VGXI, Inc. Names Jeff Whitmore as New Chief Commercial Officer
Leading plasmid DNA CDMO VGXI, Inc. announces the appointment of Jeff Whitmore as its new Chief Commercial Officer. VGXI Inc., a distinguished Texas-based Contract Development and Manufacturing Organization (CDMO) specializing in the production of plasmid DNA and RNA biopharmaceuticals, is pleased to announce the appointment of Mr. Jeff Whitmore as Chief Commercial Officer (CCO). With… Read More »
VGXI, Inc. Names James Smith as New Chief Accounting Officer
Industry-recognized plasmid DNA contract manufacturer VGXI, Inc. expands its leadership team with the addition of James Smith as Chief Accounting Officer. VGXI Inc., a leading contract development and manufacturing organization (CDMO) for plasmid DNA, is pleased to announce the appointment of Mr. James Smith as its new Chief Accounting Officer (CAO). Mr. Smith brings… Read More »
VGXI Celebrates the Grand Opening for its New Headquarters and Manufacturing Facility
With original operations based in The Woodlands, TX, industry recognized plasmid DNA contract manufacturer VGXI, Inc. celebrated the official Grand Opening of its new headquarters and expanded manufacturing facility in Conroe, TX. VGXI, Inc., a specialized contract developer and manufacturer (CDMO) of nucleic acid biopharmaceuticals including gene therapies, DNA vaccines, and RNA medicines, celebrated the… Read More »
VGXI Announces Grand Opening Celebration for New Headquarters and Manufacturing Facility
Specialized plasmid DNA contract manufacturer VGXI, Inc. announces date for the Grand Opening celebration of its new headquarters and expanded manufacturing facility in Conroe, TX. VGXI, Inc., an industry-leading contract developer and manufacturer (CDMO) of nucleic acid biopharmaceuticals including gene therapies, DNA vaccines, and RNA medicines, announces the official Grand Opening celebration for its new… Read More »
VGXI Celebrates First Look Event at New Manufacturing Facility
VGXI opened the doors of its new headquarters and manufacturing facility on 09Apr22 to provide friends and employee families a first look inside and outside the new site! As production is nearing completion, the event was an opportunity for employees and their families to tour the production suites, labs, and office spaces before the official… Read More »
VGXI Official COVID-19 Statement
To our Valued Clients and Business Partners, VGXI’s top priority is to continue delivering the highest quality DNA products and services while ensuring the security and safety of our team. VGXI is actively monitoring the evolving situation and will continue to provide updates as new information becomes available. Manufacturing activities have been maintained throughout the… Read More »
VGXI New Manufacturing Facility Achieves Construction Milestones In Advance of 2022 Operational Date
Specialized GMP contract manufacturer VGXI, Inc. announced multiple construction milestones have been reached for its new headquarters and expanded manufacturing facility in Conroe, TX. The Woodlands, TX – VGXI, Inc., an industry leading contract developer and manufacturer (CDMO) for nucleic acid biopharmaceuticals including DNA vaccines and gene therapies, announced that its new headquarters and manufacturing… Read More »
VGXI, Inc. Partners with Rare Trait Hope Fund in Support of Gene Therapy for Rare Disease, AGU
Industry leading plasmid DNA Manufacturer VGXI, Inc. partners with Rare Trait Hope Fund in support of a gene therapy for the rare genetic disease, Aspartylglucosaminuria (AGU). The Woodlands, TX – Contract developer and manufacturer VGXI, Inc., which specializes in production of nucleic acid-based biopharmaceuticals for DNA vaccines and gene therapy applications, announced it has been… Read More »
VGXI Celebrates Topping Out for New Headquarters and Manufacturing Facility in Conroe, TX
Texas-based plasmid DNA Manufacturer VGXI, Inc. Celebrates the Topping Out for its New Headquarters and Expanded Manufacturing Facility. The Woodlands, TX – VGXI, Inc., a highly specialized contract developer and manufacturer for DNA-based biopharmaceuticals, celebrated a significant milestone for its new headquarters and manufacturing facility with a topping out ceremony on Monday, April 19, 2021…. Read More »
VGXI and Geneos Therapeutics Expand Partnership for Personalized Cancer Immunotherapies
Texas-based GMP Plasmid CDMO VGXI, Inc. and Geneos Therapeutics, Inc. Expand their Clinical Manufacturing Supply Agreement in Support of Geneos’ Ongoing GT-30 Phase Ib/IIa Clinical Trial for advanced hepatocellular carcinoma (HCC). The Woodlands, TX – VGXI, Inc., an industry leading manufacturer for pre-clinical through cGMP clinical plasmid DNA, announced that its partner Geneos Therapeutics, Inc…. Read More »
VGXI Official Update Following Winter Storm Uri
To our Valued Clients and Business Partners, Thank you for everyone’s concern regarding the severe winter storm conditions that swept through Texas during the week of 15Feb21. The VGXI offices remained closed for the week to ensure the safety of all our team members as they faced challenges from icy road conditions, power outages, and… Read More »
VGXI Breaks Ground for New Manufacturing Facility in Conroe, TX
Plasmid DNA Manufacturer VGXI, Inc. Breaks Ground for New Conroe-based Manufacturing Facility. The Woodlands, TX – VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, held a groundbreaking ceremony on November 10, 2020 for its new greenfield manufacturing facility. The milestone event was hosted by VGXI in accordance with CDC COVID-19… Read More »